Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2119-2127

  Lorenzen, Sylvie ^a   Blank, Susanne ^b   Lordick, Florian ^c   Siewert, Jörg Rüdiger ^a   Ott, Katja ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTRECTOMY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR LOCALIZATION; ULTRASOUND;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84865142244     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2254-1     Document Type: Article

References (53)

1. De Vita F, Giuliani F, Galizia G, et al.Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18(6):120-3.
2. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesopha-geal cancer. N Engl J Med. 2006;355:11-20.
3. Ott K, Sendler A, Becker K, Dittler HJ, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003;6:159-67. (Pubitemid 37221566)
4. Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O et al. Final results of a randomized trial comparing preopera-tive 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25(18): 4510.
5. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-8.
6. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20. (Pubitemid 350044801)
7. Persiani R, D'Ugo D, Rausei S, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preopera-tive chemotherapy and D2-gastrectomy. J Surg Oncol. 2005;89: 227-36. (Pubitemid 40333529)
8. Lordick F, Stein HJ, Peschel C, Siewert JR.Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-51. (Pubitemid 38624660)
9. Ajani JA, Roth JA, Ryan B, et al. Evaluation of pre-and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990;8: 1231-8. (Pubitemid 20195634)
10. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229: 303-8. (Pubitemid 30191763)
11. Rohatgi PR, Mansfield PF, Crane CH, et al. Surgical pathology stage by American joint commission on cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006;107:1475-82. (Pubitemid 44546906)
12. Fink U, Schuhmacher C, Stein HJ, et al.Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg. 1995;82:1248-52.
13. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30. (Pubitemid 37151509)
14. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102:1600-7.
15. Ninomiya Y, Yanagisawa A, Kato Y, Kitagawa T, Ishihara S, Nakajima T. Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol. 1999;125:699-706.
16. Nagashima F, Boku N, Ohtsu A, et al. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol. 2005;35:714-9. (Pubitemid 43091656)
17. Jhawer M, Coit D, Brennan M, et al. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol. 2009;32:356-62.
18. Mansour JC, Tang L, Shah M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14: 3412-8. (Pubitemid 350160134)
19. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg. 1998;228:449-61. (Pubitemid 30194389)
20. Alakus H, Hölscher AH, Grass G, et al. Extracapsular lymph node spread: a new prognostic factor in gastric cancer. Cancer. 2010;116:309-15.
21. Baiocchi GL, Tiberio GA, Minicozzi AM, et al. A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg. 2010;252:70-3.
22. Bilici A, Seker M, Ustaalioglu BB, et al. Prognostic significance of perineural invasion in patients with gastric cancer who underwent curative resection. Ann Surg Oncol. 2010;17:2037-44.
23. Choi MG, Sung CO, Noh JH, et al. Mucinous gastric cancer presents with more advanced tumor stage and weaker beta-cate-nin expression than nonmucinous cancer. Ann Surg Oncol. 2010; 17:3053-8.
24. Mikami K, Maekawa T, Shinohara T, et al. Predictive factors of early recurrent death after a curative resection of gastric cancer. Int Surg. 2009;94:144-8.
25. Marchet A, Mocellin S, Ambrosi A, et al. The prognostic value of N-ratio in patients with gastric cancer: validation in a large, multicenter series. Eur J Surg Oncol. 2008;34:159-65.
26. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg. 2007;245:543-52. (Pubitemid 46555657)
27. Johnson H, Belluco C, Masood S, Azama A, Kahn L, Wise L. Preoperative factors of prognostic significance in gastric cancer. J Natl Med Assoc. 1995;87:423-6.
28. Park SR, Kim MJ, Ryu KW, et al. Prognostic value of preoper-ative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of pre-operative treatment. Ann Surg. 2010;251:428-35.
29. Shin SH, Bae JM, Jung H, et al. Clinical significance of the discrepancy between preoperative and postoperative diagnoses in gastric cancer patients. J Surg Oncol. 2010;101:384-8.
30. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert Jr. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1-9. (Pubitemid 351464481)
31. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol. 1996;14:1818-28. (Pubitemid 26185457)
32. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-9. (Pubitemid 28502569)
33. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965; 64:31-49.
34. Ott K, Fink U, Becker K, et al. Prediction of response to pre-operative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21: 4604-10. (Pubitemid 46594034)
35. Ott K, Lordick F, Becker K, et al. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis. 2008;23:773-82.
36. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012-8. (Pubitemid 351551110)
37. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert Jr. Surgical factors influence the outcome after Ivor-Lewis esopha-gectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol. 2009;16:1017-25.
38. Bader FG, Lordick F, Fink U, et al. Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie. 2008;31:366-72. (Pubitemid 351967573)
39. Greene FL, Page DL, Fleming ID, et al, editors. AJCC cancer staging manual. 6th ed. Springer: New York; 2002.
40. Stemmermann GN, Brown C. A survival study of intestinal and diffuse types of gastric carcinoma. Cancer. 1974;33:1190-5.
41. Chiaravalli AM, Cornaggia M, Furlan D, et al. The role of his-tological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch. 2001;439:158-69. (Pubitemid 32758909)
42. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol. 2003;21:3647-50. (Pubitemid 46594058)
43. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol. 2002;9:27-34. (Pubitemid 34262894)
44. Marubini E, Bonfanti G, Bozzetti F, et al. A prognostic score for patients resected for gastric cancer. Eur J Cancer. 1993;29A: 845-50. (Pubitemid 23083613)
45. Kologlu M, Kama NA, Reis E, Doganay M, Atli M, Dolapci M. A prognostic score for gastric cancer. Am J Surg. 2000;179: 521-6.
46. Costa ML, de Cássia Braga Ribeiro K, Machado MA, Costa AC, Montagnini AL. Prognostic score in gastric cancer: the importance of a conjoint analysis of clinical, pathologic, and therapeutic factors. Ann Surg Oncol. 2006;13:843-50. (Pubitemid 43727369)
47. Green D, Ponce de Leon S, Leon-Rodriguez E, Sosa-Sanchez R. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol. 2002;25:84-9. (Pubitemid 34131036)
48. Harrison JD, Fielding JW. Prognostic factors for gastric cancer influencing clinical practice. World J Surg. 1995;19:496-500.
49. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer. 2000;36:390-6. (Pubitemid 30116737)
50. Schuhmacher CP, Fink U, Becker K, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with eto-poside, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91:918-27.
51. Solcia E, Klersy C, Mastracci L, et al. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch. 2009;455:197-211.
52. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 1996;14:176-82. (Pubitemid 26020011)
53. Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127-43.